Passage BIO, Inc. (PASG) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2025. Passage BIO, Inc. is a clinical-stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases. The company's lead product candidate, PBFT02, is a gene replacement therapy for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). The company operates as a single segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Loss | $(9,385) | $(15,991) | $(24,790) | $(32,702) |
| Net Loss Per Share (Basic/Diluted) | $(2.96) | $(5.09) | $(7.83) | $(10.87) |
| Research & Development Expenses | $5,814 | $10,430 | $13,551 | $21,965 |
| General & Administrative Expenses | $4,520 | $6,510 | $10,605 | $13,025 |
| Impairment of Long-Lived Assets | $0 | $438 | $2,637 | $438 |
| Cash and Cash Equivalents (End of Period) | $57,626 | $24,770 | $57,626 | $24,770 |
| Accumulated Deficit | $(684,025) | $(627,170) | $(684,025) | $(627,170) |
| Operating Cash Flow (YTD) | $(20,177) | $(32,065) | $(20,177) | $(32,065) |
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by approximately 41% for the six months ended June 30, 2025, compared to the prior year period. This was driven by a 38% reduction in R&D expenses and a 19% reduction in G&A expenses.
- Restructuring Impact: In January 2025, the company reduced its workforce by approximately 55% and ceased lab operations in Hopewell, New Jersey. This resulted in a $2.6 million impairment charge for long-lived assets (laboratory equipment) in the first half of 2025, compared to $0.4 million in the same period in 2024.
- Liquidity Improvement: Cash and cash equivalents increased from $37.6 million at year-end 2024 to $57.6 million at June 30, 2025. This increase was primarily due to the maturity and sale of marketable securities ($39.0 million) and a net increase in cash from investing activities, offsetting operating cash burn.
- Revenue Recognition: The company received $9.7 million in non-refundable payments related to the Gemma sublicense and transition services agreements. However, no revenue was recognized in the period as the company has not yet met the criteria for revenue recognition under ASC 606 due to Gemma's limited operating history.
Guidance, Outlook, and Risks
- Cash Runway: Management expects existing cash and cash equivalents ($57.6 million) to fund operating expenses and capital expenditure requirements into the first quarter of 2027.
- Clinical Progress (PBFT02):
- Biomarker Data: Dose 1 of PBFT02 resulted in robust increases in CSF progranulin (PGRN) levels, exceeding healthy adult control ranges. Plasma neurofilament light chain (NfL) levels showed a 4% increase vs. baseline, contrasting with the expected ~28% annual increase in untreated patients.
- Safety: Three of eight patients experienced serious adverse events (SAEs), including venous sinus thrombosis and pulmonary embolism. The protocol was amended to include prophylactic anticoagulation.
- Next Steps: The company plans to begin enrollment in Cohort 3 (FTD-GRN) and Cohorts 4/5 (FTD-C9orf72) upon protocol acceptance. Regulatory feedback on registrational trial design is expected in the first half of 2026.
- Reverse Stock Split: A 1-for-20 reverse stock split was effected on July 14, 2025, to regain compliance with Nasdaq listing requirements. All share data in the filing has been retroactively adjusted.
- Key Risks:
- Capital Needs: The company has no products approved for sale and will require substantial additional capital to continue operations. Failure to raise capital could force delays or termination of programs.
- Collaboration Dependence: The company relies on Gemma Biotherapeutics for preclinical research and development of its pipeline following the outlicense of pediatric lysosomal programs.
- Manufacturing: Reliance on third-party manufacturers (Catalent) for clinical supply introduces risks regarding capacity, quality, and cost.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $20.2 million operating cash burn for the first half of 2025 against the projected runway into Q1 2027.
- Revenue Recognition Criteria: Monitor the status of the $9.7 million in deferred payments from Gemma and the specific conditions required to recognize this as revenue.
- Clinical Trial Safety: Review the impact of the amended protocol (prophylactic anticoagulation) on patient enrollment rates and safety profiles in upcoming cohorts.
- ATM Facility Capacity: Confirm the remaining capacity under the At-The-Market (ATM) facility ($15.8 million as of June 30, 2025) and the company's ability to utilize it given Nasdaq "baby shelf" rules.
- Lease Obligations: Assess the company's ability to manage significant lease liabilities ($24.7 million total) while subleasing portions of its office and lab space to offset costs.